Table 3.
Concomitant antihyperglycaemic medications at baseline and EOS
| Antihyperglycaemic medication, n (%) | Baseline (n = 215) | End of in-study observation period (n = 215) |
|---|---|---|
| Metformin | 167 (77.7) | 165 (76.7) |
| Sulphonylurea | 47 (21.9) | 34 (15.8) |
| Thiazolidinediones | 8 (3.7) | 8 (3.7) |
| DPP-4i | 36 (16.7) | 11 (5.1) |
| SGLT-2i | 83 (38.6) | 79 (36.7) |
| Other GLP-1RA | 27 (12.6) | 1 (0.5) |
| Basal insulin | 48 (22.3) | 47 (21.9) |
| Premixed insulin | 26 (12.1) | 27 (12.6) |
| Fast-acting insulin | 30 (14.0) | 20 (9.3) |
| Other glucose-lowering drugs | 2 (0.9) | 2 (0.9) |
| No medication | 5 (2.3) | 11 (5.1) |
Data are based on the full analysis set (n = 215)
DPP-4i dipeptidyl peptidase-4 inhibitor, EOS end of study, GLP-1RA glucagon-like peptide-1 receptor agonist, SGLT-2i sodium–glucose cotransporter-2 inhibitor